anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adequate use item information and subject's condition criterion information are determined in advance. Actual use item information and actual subject's condition information are inputted. The actual use item information includes information of at least one used medical device and information of at least one used medicine. The actual subject's condition information indicates biological conditions of the subject after conduction of the inspection. The actual use item information is compared with the adequate use item information and the actual subject's condition information is compared with the subject's condition criterion information so that pieces of information with difference therebetween are extracted as difference information. Whether the conducted specific medical inspection was carried out adequately or not is determined based on the difference information.
The invention relates to taenia multiceps protective antigen enolase TmENO recombinant protein with immunizing protection and a prepared method and application thereof. Amino acid sequence of the recombinant protein is GenBank. Amino acid sequence of ORF sequence encoding of accession number is SEQ No.5. Gene sequence of encoding gene sequence according to escherichia coli prefered codons to optimize is SEQ No.6. The recombinant protein can obviously reduce the number of cysts parasitized in sheep brains, and immunizing protection is achieved. Related experiments show that high title antibodies can be produced after animals are immunized by the recombinant protein, and the stronger immunizing protection can be created to taenia multiceps egg attack infection. The TmENO recombinant protein is a candidate target of coenurosis vaccine development and can be used for immunoprophylaxis of the coenurosis.
The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
In the active comparator condition, participants will complete the same 5-week eCBTi program, but will not be wearing an EEG headband during the intervention. As part of the sleep restriction therapy component of CBTi, participants will be asked to follow an individualized sleep window (i.e., bed and wake schedule) which will be adjusted each week based on the subjective sleep data derived from their sleep diary of the previous week, as is typically done during classical CBTi. Participants will not receive any EEG-based sleep report during the intervention.
All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
PURPOSE: To obtain an antimicrobial preparation exhibiting excellent antimicrobial activity against the aggregate and lump of microorganisms, such as a biofilm or plaque, which can substantially not be controlled with an antimicrobial agent a lone. CONSTITUTION: The antimicrobial preparation contains 0.001-10wt.% of arginine or its derivative and 0.001-10wt.% of a compound exhibiting antimicrobial activity. The further addition of 0.005-5wt.% of at least a surfactant selected from a nonionic surfactant and an amphoteric surfactant to the antimicrobial preparation gives the more excellent antimicrobial effect. The compound exhibiting the antimicrobial activity includes cationic antimicrobial agents (e.g. cetylpyridinium chloride), fluorides, natural antimicrobial agents (e.g. thymol, oil-soluble glycyrrhiza extract, a polyphenol), trichlosan, and isopropylmethylphenol. The nonionic surfactant is preferably a polyethylene oxide-polypropylene oxide block copolymer, and the amphoteric surfactant is preferably a palm oil fatty acid amide propylbetaine.
A medical device is disclosed. The medical device includes an RFID reader for receiving information from at least one RFID transponder. The medical device also includes a memory for storing a database and at least one processor for processing information. Also, a remote controller for a medical device is disclosed. The remote controller includes an information receiver for receiving information related to food. The infusion device also includes a memory for storing a database and at least one processor for processing information. A method for use in a medical device is also disclosed. The method includes receiving information from an RFID transponder related to food. Also, the processing the information by comparing the information to a database is included in the method. The method also includes determining the acceptability of the food and providing information related to acceptability to the user.
Patients receive ¹⁸FDG IV, then 60 minutes later undergo simultaneous MRI and PET scanning. During this scanning period, patients will receive gadoterate meglumine IV to obtain post-contrast MRI. Total scanning time will take 45-60 minutes.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a composition for topical use as an emulsion for treatment of inflammatory and hyperproliferative cutaneous diseases and cutaneous symptoms of immune-mediated diseases. The composition has a compound of class FK506 taken in amount from 0.01 to 10+ACU- by weight, physiologically acceptable alkanediol, diol ester or alcohol diester containing up to 8 carbon atoms as a solvent of compound of class FK506 taken in amount from 5 to 50+ACU- by weight, unsaturated aliphatic C 8 -C 22 -alcohol as a stabilizing agent in weight ratio between compound of class FK506 and unsaturated aliphatic alcohol from 1:1000 to 1:5 and water. Method of treatment of inflammatory or hyperproliferative cutaneous diseases involves application of indicated composition on patient skin. Composition for topical use shows stability, good skin tolerance, high rate of penetration across skin and high efficiency in using. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 8 cl, 2 tbl
Background: Lung cancer remains the leading cause of cancer deaths in the United States despite declining incidence and improved outcomes because of advancements in early detection and development of novel therapies. Accurate mediastinal lymph node staging is crucial for determining prognosis and guiding treatment decisions, particularly for non-small cell lung cancer (NSCLC). Materials and Methods: A systematic search of PubMed was conducted to identify English language articles published between January 2010 and January 2024 focusing on preoperative lymph node staging in adults with NSCLC. Case series, observational studies, randomized trials, guidelines, narrative reviews, systematic reviews, and meta-analyses were included. Results: Various imaging modalities, surgical and nonsurgical procedures for mediastinal lymph node staging were reviewed, including positron emission tomography with computed tomography, cervical mediastinoscopy, video-assisted cervical mediastinoscopy, anterior mediastinotomy, video-assisted thoracoscopy, endobronchial ultrasound-guided fine needle aspiration (EBUS-FNA), transesophageal endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), and computed tomography-guided percutaneous lymph node biopsy. EBUS-FNA emerged as the preferred initial staging procedure because of its high sensitivity and low complication rate. Combining it with other procedures or confirmatory testing may be helpful in determining appropriate treatment. Conclusions: Although cervical mediastinoscopy remains a valuable confirmatory procedure in select cases, its role as a first-line staging modality is diminishing with the widespread adoption of EBUS-FNA and EUS-FNA. The combination of EBUS-FNA and EUS-FNA allows access to nearly all mediastinal lymph node stations with high diagnostic accuracy. Future research may further refine the selection criteria for invasive mediastinal staging procedures, ultimately optimizing patient outcomes in the management of NSCLC.
PROBLEM TO BE SOLVED: To provide a combination composed of milk of immunized cow and a vaccine containing an antibody obtained from the immunized cow, giving tolerance against the antibody to mammals by the intake of the milk and enabling heterologous passive immunization of mammals without causing anaphylactic reaction, etc. SOLUTION: This combination is produced by combining (A) a food (preferably cow's milk) useful for immunotherapy, originated from the milk of an animal of the family Bovidae (preferably cow) immunized with an antigen (preferably bacterial antigen and bee toxin) and containing an antibody having increased titer sufficient for inducing immunity tolerance to the object and (B) a vaccine containing a carrier and an antibody (preferably IgG, etc.) obtained from a bovine animal immunized with the above antigen. The component B is administered after inducing the tolerance against the antibody by repeatedly administering the component A to a mammal. The antibody of the component B is preferably obtained from the milk or serum of an animal of the family Bovidae. The component B is preferably administered by intramuscular injection or intravenous injection.
A high-level of motor control often requires complex processing of sensory information, which likely corresponds to the neural correlates for mental imagery of movement. Such cognitive aspects of motor control may underlie other cognitive functions, such as mental calculation. The present transcranial magnetic stimulation (TMS) study is aimed to characterize the relation between cognitive processing and motor control. Based on our previous results from neuroimaging experiments, we hypothesize that the ability to process information for motor imagery would primarily be associated with the dorsal lateral premotor context (PMd) as well as the posterior parietal cortex. TMS will be used to disrupt neural processes in the limited brain structures under the coil for a short period of time (virtual lesion study). For this proposal, 15 healthy subjects will perform number-guided motor execution/imagery tasks. Both tasks will be guided by 10 visual number stimuli presented at a rate of 1.0 Hz. For the test TMS stimuli, a paired TMS stimulation will be delivered to either M1 or PMd100 (to) 150 milliseconds after 5 of the visual number stimuli. The frequency of TMS stimulation will be 1.0 Hz on average for a short period of time (10 seconds). Measurement will be accuracy of the task performance under the TMS stimulation as compared with a sham condition. We expect that the TMS stimulation to PMd will interfere with the performance of motor imagery more than the performance of motor execution. The present study will clarify the neural correlates underlying the ability of imagining movement, which is now drawing growing attention in the neuroscience community.
The present disclosure provides a neural document embedding based ontology mapping. Conventional methods that map ontology concepts across domains/species extensively take help of bridging ontologies. Initially the system receives a Human Phenotype (HP) Identification number (ID) pertaining to a phenotype. A first HP ID vector is computed from the HP ID using a trained word2vec model. A second HP ID vector is computed from the HP ID using a trained Doc2vec model. An average HP ID vector is computed based on the first HP ID vector and the second HP ID vector. A plurality of cosine similarity scores are computed based on a comparison between the average HP ID vector and a plurality of average MP ID vectors. The plurality of MP IDs are sorted based on the plurality of cosine similarity scores. The plurality of MP IDs corresponding to the HP ID are selected based on a selection threshold.
This single-arm feasibility study is conducted at Copenhagen University Hospital, Rigshospitalet, in Denmark at the Department of Pediatric Oncology and Hematology.The PI started to recruit participants March 2022. Patients with Acute Lymphoblastic Leukemia (ALL), Philadelphia positive Acute Lymphoblastic Leukemia (PH+ALL) and Lymphoblastic Lymphoma (LBL) are eligible for inclusion if their parents speak and understand Danish or English, able to manage basic treatment and care such as oral medication, mobilization, nutrition, central venous catheter care and practice good personal hygiene. The parents' competences are assessed by the PI in collaboration with a team of project- and ward nurses who know them. Participants are recruited between day 15 and 29 from diagnosis. Parents to eligible participants and adolescents aged 15+ receive oral and written information and provide written informed consent before inclusion. Children and adolescents less than 15 years of age receive oral information and provide oral consent if possible according to their age. Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
The gut microbiome, composed of the colonic microbiota and their host environment, is important for many aspects of human health. A gut microbiome imbalance (gut dysbiosis) is associated with major causes of human morbidity and mortality. Despite the central part our gut microbiome plays in health and disease, mechanisms that maintain homeostasis and properties that demarcate dysbiosis remain largely undefined. Here we discuss that sorting taxa into meaningful ecological units reveals that the availability of respiratory electron acceptors, such as oxygen, in the host environment has a dominant influence on gut microbiome health. During homeostasis, host functions that limit the diffusion of oxygen into the colonic lumen shelter a microbial community dominated by primary fermenters from atmospheric oxygen. In turn, primary fermenters break down unabsorbed nutrients into fermentation products that support host nutrition. This symbiotic relationship is disrupted when host functions that limit the luminal availability of host-derived electron acceptors become weakened. The resulting changes in the host environment drive alterations in the microbiota composition, which feature an elevated abundance of facultatively anaerobic microbes. Thus, the part of the gut microbiome that becomes imbalanced during dysbiosis is the host environment, whereas changes in the microbiota composition are secondary to this underlying cause. This shift in our understanding of dysbiosis provides a novel starting point for therapeutic strategies to restore microbiome health. Such strategies can either target the microbes through metabolism-based editing or strengthen the host functions that control their environment.
This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
OBJECTIVES: Our aim was to report an anatomic model of an autologous flap based on the internal thoracic blood supply: the pedicled thoraco-chondro-costal flap; and establish the feasibility of various types of extended tracheal replacement with this novel flap, according to a newly proposed topographic classification.
METHODS: In a cadaveric model, a cervicotomy combined with median sternotomy was performed. The incision was extended laterally to expose the chest wall. The internal thoracic pedicle was freed from its origin down to the upper limit of the delineated flap to be elevated. The perichondria and adjacent periostea were incised longitudinally to remove cartilages and adjacent rib segments, preserving perichondria and periostea. A full-thickness quadrangular chest wall flap pedicled on internal thoracic vessels was then elevated and shaped into a neo conduit to replace the trachea with the pleura as an inner lining.
RESULTS: Various types of extended non-circumferential and full-circumferential tracheal replacements were achieved with this composite flap. No anastomosis tension was noticed despite the absence of release manoeuvres.
CONCLUSIONS: This model could represent a suitable autologous tracheal substitute, which is long, longitudinally flexible and eventually transversely rigid. No microsurgical vascular anastomoses are required. The technique is reproducible. The perichondria and periostea would regenerate vascularized neo-cartilaginous rings, potentially decreasing the need for long-term stenting. The inner pleural lining could potentially transform into ciliated epithelium as shown in previous preclinical studies.
Diagnosing atrial myxoma in pregnancy is challenging because patients may present with non-specific symptoms that might be overlooked. The timing of non-obstetric operation usually depends on the nature of the disease, after careful consideration of feto-maternal safety, including the use of cardiopulmonary bypass and placental transfer of anaesthetic drug. A woman in her 30s at 18 weeks of pregnancy presented with recurring dizziness. She underwent successful myxoma excision at 20 weeks under general anaesthesia and cardiopulmonary bypass. The 6×5 cm myxoma was histologically confirmed as myxoma. Early detection of atrial myxoma in pregnancy is crucial, and a clinician has to consider the diagnosis of left atrial myxoma with mitral valve obstruction as a cause of severe dizziness. Optimal outcomes require multidisciplinary management. In this case, surgery during the second trimester of pregnancy enabled a full-term pregnancy with the patient's and foetal well-being and normal postprocedural echocardiography.
Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.

Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibodies with or without preoperative chemoradiation for LAGC.

The results of the NeoRacing study will provide important information concerning the application of PD-1 antibodies in LAGC patients during the preoperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety.
Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
Tumours in patients with head and neck cancer (HNC) are associated with a more significant decrease in quality of life compared with the rest of patients with cancer. We present a patient with pain due to HNC successfully treated with bipolar radiofrequency ablation. A man in his 70s presented with a tumour in the left V2 and V3 region, with disabling pain, Visual Analogue Scale (VAS) score of 10/10, pain on swallowing, chewing and speaking, 3 months of evolution. The patient was evaluated in the pain management department, and the interventional treatment proposed consisted of bipolar pulsed radiofrequency, followed by bipolar thermal radiofrequency of the left V2 and V3 branches with fluoroscopic guidance to achieve better control and coverage of the affected trigeminal branches. Immediately after the procedure, the patient reported a significant improvement in pain with a 0-10 VAS; hypoesthesia in the affected V2 and V3 territory was identified, but no motor weakness. The improvement in pain was maintained for 6 months with a significant improvement in quality of life and pain, which allowed him to speak, chew and swallow without pain. Later, the patient died from complications associated with the disease. The treatment approach in these patients is both pain treatment and achieving independence by allowing better speech ability and improving eating, the above as a pillar of treatment focused on improving the patient's quality of life. This approach is a potential tool in the early stage of the disease in patients with pain due to HNC.
Risk Summary

There are no human data available on the presence of eliglustat in human milk, the effects on the breastfed infant, or the effects on milk production. Eliglustat and its metabolites were present in the milk of lactating rats [see Data]. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CERDELGA and any potential adverse effects on the breastfed child from CERDELGA or from the underlying maternal condition.

Data

In a milk excretion study in the rat, a single oral dose of 30 mg/kg [14C]-labeled eliglustat was administered to lactating female rats at day 11 postpartum. Approximately 0.23% of the administered radioactivity was excreted into the milk within 24 hours of dose administration. The concentration in the milk at 24 hours post dose was 16.3-fold higher than the plasma concentration.